51 related articles for article (PubMed ID: 19896080)
1. A novel GVHD-prophylaxis with low-dose alemtuzumab in allogeneic sibling or unrelated donor hematopoetic cell transplantation: the feasibility of deescalation.
Bertz H; Spyridonidis A; Wäsch R; Grüllich C; Egger M; Finke J
Biol Blood Marrow Transplant; 2009 Dec; 15(12):1563-70. PubMed ID: 19896080
[TBL] [Abstract][Full Text] [Related]
2. Sibling donor and recipient immune modulation with atorvastatin for the prophylaxis of acute graft-versus-host disease.
Hamadani M; Gibson LF; Remick SC; Wen S; Petros W; Tse W; Brundage KM; Vos JA; Cumpston A; Bunner P; Craig MD
J Clin Oncol; 2013 Dec; 31(35):4416-23. PubMed ID: 24166529
[TBL] [Abstract][Full Text] [Related]
3. Impact of Donor Statin Treatment on Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation.
Rashid N; Gooley T; Furlong T; Lee SJ; Martin PJ; Storb R; Mielcarek M
Transplant Cell Ther; 2023 Nov; 29(11):701.e1-701.e8. PubMed ID: 37657769
[TBL] [Abstract][Full Text] [Related]
4. Phase I-II Trial of Early Azacitidine after Matched Unrelated Donor Hematopoietic Cell Transplantation.
Xu Z; Choi J; Cooper M; King J; Fiala MA; Liu J; Pusic I; Romee R; Cashen A; Jacoby MA; Stockerl-Goldstein K; Abboud C; Vij R; Uy G; Westervelt P; Walter MJ; DiPersio JF; Schroeder MA
Transplant Cell Ther; 2023 Nov; 29(11):699.e1-699.e9. PubMed ID: 37597685
[TBL] [Abstract][Full Text] [Related]
5. High-dose Alemtuzumab-Cyclosporine vs Tacrolimus-Methotrexate-Sirolimus for Chronic Graft-versus-Host Disease Prevention.
Holtzman NG; Curtis LM; Salit RB; Shaffer BC; Pirsl F; Ostojic A; Steinberg SM; Schulz E; Wilder JS; Hughes TE; Rose J; Memon S; Korngold R; Gea-Banacloche J; Fowler DH; Hakim FT; Gress RE; Bishop MR; Pavletic SZ
Blood Adv; 2024 Apr; ():. PubMed ID: 38669315
[TBL] [Abstract][Full Text] [Related]
6. Impact of GVHD on lymphoma progression: Nationwide study from Japanese Society for Transplantation and Cellular Therapy.
Watanabe M; Kanda J; Fukuda T; Uchida N; Ikegame K; Kataoka K; Kobayashi H; Ara T; Ishikawa J; Matsuoka KI; Sugio Y; Nakazawa H; Ikeda T; Atsuta Y; Kondo E; Suzuki R;
Br J Haematol; 2023 Nov; 203(3):446-459. PubMed ID: 37614023
[TBL] [Abstract][Full Text] [Related]
7. Graft Versus Leukemia: Current Status and Future Perspectives.
O'Neill AT; Chakraverty R
J Clin Oncol; 2021 Feb; 39(5):361-372. PubMed ID: 33434054
[No Abstract] [Full Text] [Related]
8. Comparison of fludarabine/melphalan (FluMel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation - a registry study on behalf of the EBMT Acute Leukemia Working Party.
Duque-Afonso J; Finke J; Ngoya M; Galimard JE; Craddock C; Raj K; Bloor A; Nicholson E; Eder M; Kim O; Valerius T; Snowden JA; Tholouli E; Crawley C; Collin M; Wilson KMO; Gadisseur A; Protheroe R; Wagner-Drouet EM; Savani BN; Spyridonidis A; Ciceri F; Nagler A; Mohty M
Bone Marrow Transplant; 2024 Feb; 59(2):247-254. PubMed ID: 38040842
[TBL] [Abstract][Full Text] [Related]
9. Immunometabolic Therapeutic Targets of Graft-versus-Host Disease (GvHD).
Mhandire K; Saggu K; Buxbaum NP
Metabolites; 2021 Oct; 11(11):. PubMed ID: 34822394
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Infectious and Noninfectious Outcomes of Monthly Alemtuzumab as a Calcineurin Inhibitor- and Steroid-Free Regimen for Pancreas Transplant Recipients.
Kaplan A; Young JH; Kandaswamy R; Berglund D; Knoll BM; Sieger G; Cavert W; Matas A; Obeid KM
Can J Infect Dis Med Microbiol; 2020; 2020():8883183. PubMed ID: 33101558
[TBL] [Abstract][Full Text] [Related]
11. Comparison of reduced-toxicity conditioning protocols using fludarabine, melphalan combined with thiotepa or carmustine in allogeneic hematopoietic cell transplantation.
Duque-Afonso J; Ihorst G; Waterhouse M; Zeiser R; Wäsch R; Bertz H; Yücel M; Köhler T; Müller-Quernheim J; Marks R; Finke J
Bone Marrow Transplant; 2021 Jan; 56(1):110-120. PubMed ID: 32591641
[TBL] [Abstract][Full Text] [Related]
12. Impact of Alemtuzumab Scheduling on Graft-versus-Host Disease after Unrelated Donor Fludarabine and Melphalan Allografts.
Green K; Pearce K; Sellar RS; Jardine L; Nicolson PLR; Nagra S; Bigley V; Jackson G; Dickinson AM; Thomson K; Mackinnon S; Craddock C; Peggs KS; Collin M
Biol Blood Marrow Transplant; 2017 May; 23(5):805-812. PubMed ID: 28212937
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic hematopoietic cell transplantation with double alkylating agents containing reduced-intensity conditioning for patients ⩾60 years with advanced AML/MDS.
Bertz H; Lübbert M; Ohneberg K; Zeiser R; Wäsch R; Marks R; Finke J
Leukemia; 2016 Dec; 30(12):2426-2429. PubMed ID: 27573558
[No Abstract] [Full Text] [Related]
14. Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016.
Ullmann AJ; Schmidt-Hieber M; Bertz H; Heinz WJ; Kiehl M; Krüger W; Mousset S; Neuburger S; Neumann S; Penack O; Silling G; Vehreschild JJ; Einsele H; Maschmeyer G;
Ann Hematol; 2016 Sep; 95(9):1435-55. PubMed ID: 27339055
[TBL] [Abstract][Full Text] [Related]
15. Reduced platelet transfusions and earlier platelet engraftment using alemtuzumab-based conditioning regimen in allogeneic stem cell transplantation.
Neumann T; Schneidewind L; Thiele T; Schulze M; Klenner AF; Busemann C; Pink D; Greinacher A; Dölken G; Krüger WH
J Cancer Res Clin Oncol; 2016 May; 142(5):1091-7. PubMed ID: 26779644
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up of therapy-related myelodysplasia and AML patients treated with allogeneic hematopoietic cell transplantation.
Finke J; Schmoor C; Bertz H; Marks R; Wäsch R; Zeiser R; Hackanson B
Bone Marrow Transplant; 2016 Jun; 51(6):771-7. PubMed ID: 26752137
[TBL] [Abstract][Full Text] [Related]
17. A comparative study of reduced dose alemtuzumab in matched unrelated donor and related donor reduced intensity transplants.
Jardine L; Publicover A; Bigley V; Hale G; Pearce K; Dickinson A; Jackson G; Collin M
Br J Haematol; 2015 Mar; 168(6):874-81. PubMed ID: 25640315
[TBL] [Abstract][Full Text] [Related]
18. The effects of CAMPATH-1H on cell viability do not correlate to the CD52 density on the cell surface.
Lee F; Luevano M; Veys P; Yong K; Madrigal A; Shaw BE; Saudemont A
PLoS One; 2014; 9(7):e103254. PubMed ID: 25050704
[TBL] [Abstract][Full Text] [Related]
19. Preemptive DLI without withdrawal of immunosuppression to promote complete donor T-cell chimerism results in favorable outcomes for high-risk older recipients of alemtuzumab-containing reduced-intensity unrelated donor allogeneic transplant: a prospective phase II trial.
Solomon SR; Sizemore CA; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
Bone Marrow Transplant; 2014 May; 49(5):616-21. PubMed ID: 24801098
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
